Exogenus T
Founded 2015 · 13 employees on LinkedIn · 1 known investors
Exogenus Therapeutics is a biotechnology company developing extracellular vesicle (exosome) technologies for regenerative medicine, with a lead candidate, EXO-101, derived from umbilical cord blood cells for inflammatory and fibrotic diseases. It focuses on the development, manufacturing (in GMP conditions), and commercialization of exosome-based therapeutics.
Founders & leadership
JS
Joana Simões CorreiaCEO
Investors · 1
Frequently asked questions
- What does Exogenus T do?
- Exogenus Therapeutics is a biotechnology company developing extracellular vesicle (exosome) technologies for regenerative medicine, with a lead candidate, EXO-101, derived from umbilical cord blood cells for inflammatory and fibrotic diseases. It focuses on the development, manufacturing (in GMP conditions), and commercialization of exosome-based therapeutics.
- Who are Exogenus T's investors?
- Exogenus T's investors include 3xP Global.